Trial Profile
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Molindone (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Acronyms CHIME 4
- Sponsors Supernus Pharmaceuticals
- 19 Oct 2020 Status changed from recruiting to completed.
- 06 Aug 2019 According to Supernus media release, enrollment in this study continues at 90% or higher. On average, a patient in the OLE study remains on SPN-810 treatment for approximately 10.7 months, which the company believes is an encouraging sign of the tolerability and efficacy of SPN-810.
- 02 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.